Group 2B: HR+ Breast Cancer; Risk Factors
Wednesday, Dec 14
2:00 pm – 3:30 pm Eastern Time (US/New York)
Poster #P3-05-26:
Association of muscle mass and density with outcomes in patients with ER positive metastatic breast cancer: correlative analysis of ECOG-ACRIN 2112
Poster author Tarah Ballinger, M.D. is also the scientist for this session
Poster #P3-01-13:
Palbociclib, ribociclib and abemaciclib in real-world data: risk of disease progression on first-line treatment of metastatic breast cancer
Mentor: Amy Beumer, Ph.D.
Amy was diagnosed with stage I breast cancer in 2017 and metastatic in 2020. In her previous life she was a biology professor teaching various microbiology and introductory biology courses as well as conducting research in drinking water microbiology and team learning. Currently, she is upping her knowledge of cancer research, advocating, and getting as much traveling, hiking, reading, gardening and time with friends and family in as possible.Twitter: @amybeumer
Scientist: Tarah Ballinger, M.D.
Dr. Tarah Ballinger’s practice philosophy is to empower her patients to engage in a shared decision-making process with honest discussions at each step of treatment. She feels it is important to individualize care and to focus on the impact of cancer care on a patient as a whole person. Her clinical interests include high-risk and survivor breast oncology, particularly the role of physical activity and exercise. Aside from medicine, Dr. Ballinger enjoys spending time with her family and friends, running and cycling.
Twitter: @TarahBallinger
